Clinical trials are the only reliable way to know whether a medical treatment actually works and is safe enough to use. Every prescription drug, vaccine, and medical device available today went through this process, and without it, doctors would be guessing based on theory rather than evidence. The system is expensive, slow, and imperfect, but it exists because the alternative (giving people untested treatments) has historically led to serious harm.
How Treatments Prove They Work
A drug can look promising in a lab and still fail in the human body. Clinical trials bridge that gap by testing treatments in real people under controlled conditions, measuring both benefits and harms with enough precision to distinguish a genuine effect from a placebo response or statistical fluke. The FDA generally requires results from two well-designed clinical trials before approving a new drug, specifically to rule out the possibility that a single positive result was due to chance or bias. For rare diseases where running multiple large trials isn’t feasible, convincing evidence from one trial can be sufficient.
This bar matters because the failure rate is high. An analysis of nearly 2,100 drug candidates tested by 18 leading pharmaceutical companies between 2006 and 2022 found that only 14.3% of drugs entering Phase I trials ultimately received FDA approval. Some companies saw rates as low as 8%. That means roughly six out of every seven drugs that appear safe and promising enough to test in humans still don’t make it to your pharmacy shelf. Without trials catching those failures, ineffective or dangerous treatments would reach patients routinely.
What Each Phase Actually Tests
Clinical trials don’t jump straight to testing whether a drug works. They follow a phased structure designed to catch problems early, before large numbers of people are exposed.
- Phase I enrolls 20 to 80 people and focuses almost entirely on safety. Researchers are looking for side effects, figuring out safe dosage ranges, and watching how the body processes the drug.
- Phase II expands to 100 to 300 people and shifts toward effectiveness. Does the treatment actually do what it’s supposed to do? Safety monitoring continues.
- Phase III involves 1,000 to 3,000 people and compares the new treatment against existing options or a placebo. This is where researchers confirm effectiveness, identify less common side effects, and gather the data the FDA needs for an approval decision.
- Phase IV happens after approval, tracking the drug’s safety in the general population. Rare side effects that didn’t show up in smaller trials sometimes surface here, and researchers learn more about how the drug performs in everyday clinical use rather than controlled study conditions.
This entire clinical phase takes an average of about 95 months, roughly eight years, and accounts for 69% of total research and development costs. A 2024 analysis estimated that clinical trials alone cost an average of $117.4 million per drug, making up about 68% of out-of-pocket development spending. After factoring in the cost of all the drugs that fail along the way, the total cost per approved drug reaches roughly $879 million.
Protecting People in the Process
The ethical framework around clinical trials exists because of past abuses. Today, anyone entering a trial must go through an informed consent process that covers the study’s purpose, expected duration, potential risks and discomforts, possible benefits, alternative treatments that exist, how their data will be kept confidential, and what compensation or medical care is available if something goes wrong. Participation is always voluntary, and that voluntariness has to be more than a formality. The consent process must minimize any possibility of coercion or pressure.
Independent bodies called Institutional Review Boards review and approve every trial before it begins. They examine the study design, the consent materials, and the safeguards in place. They also provide ongoing oversight: if new safety information emerges during a trial, the IRB reviews it and can require that participants be informed of findings that might change their willingness to continue. For studies involving people who may be especially vulnerable to pressure, such as prisoners or people with cognitive impairments, IRBs can require additional protections.
Why the FDA Weighs Benefits Against Context
FDA approval isn’t a simple pass/fail test on safety. Reviewers weigh a drug’s benefits against its risks in the context of what patients are already facing. A cancer drug with significant side effects might be approved for a life-threatening cancer with no other treatment options, because the potential benefit of survival outweighs those risks. That same side effect profile would likely be unacceptable for a drug treating a mild, non-threatening condition. This context-dependent evaluation is only possible because clinical trials generate detailed, structured data on both the upsides and downsides of a treatment.
This is one of the less obvious reasons trials matter. They don’t just tell regulators whether a drug works. They provide the granular safety data that allows for nuanced decisions about who should receive which treatments, at what doses, and with what monitoring.
Diversity in Trials Affects Everyone
A treatment tested primarily in one population may not work the same way in another. Differences in genetics, metabolism, body composition, diet, and coexisting health conditions can all influence how a drug performs. When clinical trials fail to include diverse participants, the safety and effectiveness data they generate may not apply equally to everyone who will eventually take the drug.
This is not a hypothetical problem. Black Americans account for 12.4% of pancreatic cancer diagnoses in the United States but only 8.2% of participants in pancreatic cancer clinical trials. That gap is common across disease areas, and it’s especially troubling because minority racial and ethnic populations often carry a disproportionate burden of chronic disease. The very people who might benefit most from new therapies are the least represented in the research that develops them. The FDA has pushed the pharmaceutical industry to address this through changes to study design, eligibility criteria, and enrollment practices, but the gap persists.
From Lab to Patient: What Trials Make Possible
The practical impact of clinical trials shows up in treatments that would have been unimaginable without systematic human testing. Researchers have found that injecting patients’ own stem cells (harvested from fat tissue) into a vein before dialysis can help prevent the inflammation and vein narrowing that makes dialysis progressively harder to tolerate. That finding could extend the time millions of people can remain on dialysis before needing a kidney transplant.
In epilepsy treatment, clinical research has moved beyond the old one-size-fits-all approach to brain stimulation. By mapping each patient’s unique brain wave patterns, physicians can now target stimulation precisely where it’s most effective. The long-term goal is to quiet the seizure network so thoroughly that the brain essentially forgets it, potentially moving from seizure control to a cure. In type 1 diabetes research, scientists discovered that a sugar molecule cancer cells use to hide from the immune system might also be used to protect transplanted insulin-producing cells, potentially eliminating the need for lifelong immune-suppressing drugs after a transplant.
None of these advances would be possible without the structured, phased process of clinical trials. Each one started as a hypothesis and was tested in progressively larger groups of people, generating the evidence needed to know whether it truly helps, who it helps, and what risks come with it. That process is slow and costly by design, because the cost of skipping it is measured in human lives.